Errata (DOI:10.1016/S1470-2045(09)70311-0);Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 21-28

  Bonner, James A ^a   Harari, Paul M ^b   Giralt, Jordi ^c   Cohen, Roger B ^d   Jones, Christopher U ^e   Sur, Ranjan K ^f   Raben, David ^g   Baselga, Jose ^c   Spencer, Sharon A ^a   Zhu, Junming ^h   Youssoufian, Hagop ^h   Rowinsky, Eric K ^h   Ang, K Kian ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d FOX CHASE CANCER CENTER   (United States)

^e Radiological Associates of Sacramento Medical Group Inc   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF COLORADO   (United States)

^h ImClone Systems Inc   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ERUPTION; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INJECTION SITE REACTION; LARYNX CARCINOMA; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMATITIS;

EID: 73249143536     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70393-6     Document Type: Erratum

References (43)

1. Jesse R.H. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope 85 (1975) 1424-1429
2. Strong E.W., Henschke U.K., Nickson J.J., et al. Preoperative x-ray therapy as an adjunct to radical neck dissection. Cancer 19 (1966) 1509-1516
3. Peters L.J., Ang K.K., and Thames H.D. Accelerated fractionation in the radiation treatment of head and neck cancer. Acta Oncol 27 (1988) 185-194
4. Bryce D.P., and Rider W.D. Pre-operative irradiation in the treatment of advanced laryngeal carcinoma. Laryngoscope 81 (1971) 1481-1490
5. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
6. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomised trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC Trial. J Clin Oncol 24 (2006) 2873-2878
7. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
8. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
9. Calais G., Alfonsi M., Bardet E., et al. Randomised trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
10. Pignon J.P., le Maitre A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92 (2009) 4-14
11. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
12. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomised German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
13. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 suppl (2000) 47S-53S
14. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
15. Ang K.K., Berkey B.A., Tu V., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
16. Bonner J.A., Maihle N.J., Folven B.R., Christianson T.J.H., and Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29 (1994) 243-247
17. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
18. Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14 (1999) 451-463
19. Goldstein N., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
20. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3 (1997) 2703-2707
21. Fan Z., Masui H., Altas I., et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53 (1993) 4322-4328
22. Li S., Schmitz K.R., Jeffrey P.D., et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 (2005) 301-311
23. Fan Z., Lu Y., Wu X., et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269 (1994) 27595-27602
24. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 3234-3243
25. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
26. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (2007) 2040-2048
27. Saltz L.B., Kies M.S., Abbruzzese J.L., et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 21 suppl (2003) abstr 817.
28. Rougier P, Stroiakovski D, Köhne C, et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA, USA; Jan 15-17, 2009. abstr 443.
29. Gatzemeier U, von Pawel J, Vynnchenko I, et al. FLEX: cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1st-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL, USA; Nov 13-15, 2008. abstr 8.
30. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
31. Pocock S.J., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115
32. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
33. Lewis S., and Clarke M. Forest plots: trying to see the wood and the trees. BMJ 322 (2001) 1479-1480
34. Curran D., Giralt J., Harari P.M., et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25 (2007) 2191-2197
35. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
36. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers (Version 1, 2007). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed April 1, 2009).
37. Bonner J., Harari P.M., Giralt J., et al. The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. Int J Radiat Oncol Biol Phys 63 suppl 1 (2005) S73
38. Lenz J.H., Cutsem E.V., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 (2006) 4914-4921
39. Langer C.J., Lee J.W., Patel U.A., et al. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 26 suppl (2008) abstr 6006.
40. National Institute for Health and Clinical Excellence. Technology appraisal guidance 145, Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. http://guidance.nice.org.uk/TA145 (accessed Sept 10, 2009).
41. Caudell J.J., Schaner P.E., Meredith R.F., et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 73 (2009) 410-415
42. Caudell J.J., Sawrie S.M., Spencer S.A., et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 71 (2008) 676-681
43. Lefebvre J., Pointreau Y., Rolland F., et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomised phase II TREMPLIN study. Proc Am Soc Clin Oncol 27 suppl (2009) 303s